[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].
Fiche publication
Date publication
septembre 2018
Journal
Revue des maladies respiratoires
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MENNECIER Bertrand
Tous les auteurs :
Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M
Lien Pubmed
Résumé
Programmed cell death-ligand 1 (PD-L1) is a checkpoint receptor that facilitates immune evasion by tumor cells, through interaction with programmed cell death-1 (PD-1), a receptor expressed by T-cells. Durvalumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 interaction with PD-1 on T-cells, countering the tumor's immune-evading tactics. Phase I/II studies demonstrated durable responses and manageable tolerability in heavily pre-treated patients with non-small cell lung cancer (NSCLC).
Mots clés
Anti-PD-L1, CBNPC, Durvalumab, Early stage, NSCLC, Neoadjuvant, Néo-adjuvant, Stade précoce
Référence
Rev Mal Respir. 2018 Sep 19;: